Madrigal Pharmaceuticals, Inc. (MDGL): Long-Term Debt
$339.88M
As of 2025-12-31
$340.79M
As of 2026-06-30
+69.6%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $339.88M | +189.1% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $117.57M | +1.8% | 2025-02-26, Balance as of period end |
| 2023-12-31 | $115.48M | +65.7% | 2024-02-28, Balance as of period end |
| 2022-12-31 | $69.67M | n/a | 2023-03-03, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $339.88M | +189.1% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $1.81B | +44.6% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $163.66M | -8.7% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $993.95M | +0.2% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $589.70M | -15.8% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $372.19M | -36.4% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $343.97M | -21.3% |
| Insmed Inc (INSM) | 2025-12-31 | $546.77M | -51.3% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $93.16M | +12.5% |
Compare MDGL, IONS, HRMY, PBH side by side · Screen every company in Pharmaceutical Preparations ↗